Skip to content
Search

Latest Stories

Pharmacy Business Awards postponed to March 23

The 21st edition of the Pharmacy Business Awards have been postponed due to a dramatic rise in the number of Omicron cases nationwide in recent months.

The in-person event -- initially scheduled to be held on February 3 -- will now be held on Wednesday March 23 in central London.


The awards dinner hosted by the Asian Media Group -- owners of Pharmacy Business -- was initially scheduled to be held on February 3.

“Given the uncertainties around Omicron and the impact it could have on our community, we have taken the difficult decision to postpone the twenty-first edition of the Pharmacy Business Awards," an AMG spokesperson said, adding: "We feel this is the best and safest decision for our award winners, guests and partners."

Event organizers expect a senior Government minister and leading figures from the sector to join the celebrations which are held annually to recognize the very best of community pharmacy up and down the country.

The previous edition -- the 20th annual Pharmacy Business Awards -- slated to be held in 2020 were also postponed because of the Coronavirus pandemic and were eventually held virtually on January 21, 2021.

"We hope to be back to our normal schedule and host the 22nd Pharmacy Business Awards later this year," the AMG spokesperson added.

The Pharmacy Business Awards -- one of the sector's most prestigious and coveted awards -- are given away in a number of categories to celebrate excellence in community pharmacy.

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less